ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 22 of 47
Up
УЖМБС 2019, 4(1): 161–165
https://doi.org/10.26693/jmbs04.01.161
Clinical Medicine

Clinically Isolated Syndrome of Multiple Sclerosis: Clinical and Paraclinical Features

Shulga O. D.
Abstract

Clinically isolated syndrome is the first clinical attack of multiple sclerosis. Clinical signs of clinically isolated syndrome depend on anatomical location of foci/focus of demyelination and are manifested as unilateral neuritis of the optic nerve, focal supratentorial or brainstem, cerebellar syndrome or partial myelopathy. Up to 70% of patients with clinically isolated syndrome will develop multiple sclerosis in future. There are five phenotypes of clinically isolated syndrome. In case of clinically isolated syndrome lesions can be present or absent on brain MRI. Clinically isolated syndrome is relatively recently isolated in an independent nosological unit, so the number of works dealing with its features is insufficient, in Ukraine as well. The purpose of the study was to determine the clinical and structural features of the brain in patients with clinically isolated syndrome. Material and methods. We conducted a longitudinal study of 30 patients who attended Volyn Regional Clinical Hospital. We developed universal inclusion and exclusion criteria to enroll the patients into the study. This study was conducted in Ukraine for the first time. The research is an observatory, prospective, double (a patient, a researcher) examination of patients with clinically isolated syndrome of multiple sclerosis. We examined the associations between demographic, clinical, imaging features in patients with clinically isolated syndrome. MRI of the brain was performed on 1.5 T scanner Toshiba Titan Octave with a standard protocol. To assess atrophic processes, we measured 23 linear parameters for each patient twice in dynamics. Besides, 14 indices were calculated for each MRI, namely, corpus callosum index, width of lateral ventricles (right and left), width of III ventricle, frontal atrophy index, bicaudate index, and index of medial structures, Evans’ index, Huckman index, ventricular parieto-occipital index and ventricular temporal index. To conduct linear measurements, RadiAnt DICOM Viewer program was used, which is available free online (https://www.radiantviewer.com/). Statistical analysis was performed by means of the program Microsoft Excel, SPSS for Windows; standard descriptive statistics were used. Routine laboratory investigations (hematological, biochemical), as a safety measures, were performed during each visit of a patient before conducting MRI of the brain. Results and discussion. 30 patients with clinically isolated syndrome were examined aged 32.07±8.54 years old. Women predominated and comprised 27 (90%) patients. The multifocal debut of the disease was observed in 18 (60%) subjects. The EDSS score at the time of clinically isolated syndrome was 2.98±0.55 points. The average time before the second attack was 6.33±3.46 months. We revealed demyelinating lesions in 30 (100%) patients. The typical localization of demyelinating lesions in patients with clinically isolated syndrome is periventricular (including corpus callosum), juxtacortical and cortical zones according to magnetic resonance imaging. Infratentorial lesions were observed much less frequently in the clinically isolated syndrome. Contrast enhancement lesions were located in periventricular regions most frequently. Limited lesions located in cerebral cortex were active. In general, despite of clinical symptoms, active lesions of demyelination were present less than in half of patients with clinically isolated syndrome. Linear measures and indices of atrophy were also calculated. Conclusion. Clinically isolated syndrome in studied patients was presented with multifocal symptoms, with the predominant involvement of the pyramidal and cerebellar systems. Active lesions of demyelination on the stage of clinically isolated syndrome were present in almost half of cases. Periventricular (with at least one lesion involving corpus callosum) and juxtacortical lesions were the most typical in patients with clinically isolated syndrome. Further investigations are needed to describe changes of demyelination and atrophy in patients with clinically isolated syndrome in dynamics.

Keywords: clinically isolated syndrome, multiple sclerosis

Full text: PDF (Ukr) 198K

References
  1. Voloshyna NP, Gaponov YK. Vozmozhnosty magnytno-rezonansnoj tomografyy v dyagnostyke y prognoze techenyya rasseyannogo skleroza v zavysymosty ot pola y vozrasta bolnyx. Ukrayinskiy visnyk psyhonevrologiyi. 2010; 18(3): 19-23. [Russian]
  2. Kobys` TO. Prognostychne znachennya klinichnyh ta nejrovizualizacijnyh faktoriv ryzyku aktyvnosti perebigu rozsiyanogo sklerozu. Mizhnarodnyj nevrologichnyj zhurnal. 2016; 3: 46-51. [Ukrainian]
  3. Mishсhenko TS. Shulga OD, Bobryk NV, Shulga LA. Rozsiyanyj skleroz: globalni perspektyvy. Ukr med chasopys. 2014; 3: 84–7. [Ukrainian]
  4. Figueira F, Santos V, Figueira G, Silva A. Corpus callosum index: a practical method for long-term follow-up in multiple sclerosis. Arq Neuropsiquiatr. 2007; 65(4A): 931-5. https://www.ncbi.nlm.nih.gov/pubmed/18094848. https://doi.org/10.1590/S0004-282X2007000600001
  5. Gaetani L, Fanelli F, Riccucci I, Eusebi P, Sarchielli P, Pozzilli C, et al. High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. Journal of the Neurological Sciences. 2017; 379: 236-40. https://www.ncbi.nlm.nih.gov/pubmed/28716249. https://doi.org/10.1016/j.jns.2017.06.008
  6. Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation Journal of Neurology, Neurosurgery & Psychiatry. 2008; 79(11): 1236-44. https://www.ncbi.nlm.nih.gov/pubmed/18469033. https://www.ncbi.nlm.nih.gov/pmc/articles/4827711. https://doi.org/10.1136/jnnp.2007.134825
  7. Kurtzke JF. Rating Neurologic Impairment in Multiple Sclerosis an Expanded Disability Status Scale (EDSS). Neurology. 1983; 33(11): 1444–52. https://www.ncbi.nlm.nih.gov/pubmed/6685237. https://doi.org/10.1212/WNL.33.11.1444
  8. Menendez M, Arias-Carrión O. Indices of Regional Brain Atrophy: Formulae and Nomenclature. Muacevic A, Adler JR, eds. Cureus. 2015; 7(8): e295. https://doi.org/10.7759/cureus.295
  9. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012; 11(2): 157–69. https://www.ncbi.nlm.nih.gov/pubmed/22265211. https://doi.org/10.1016/S1474-4422(11)70274-5
  10. Missori P, Currà A. Progressive Cognitive Impairment Evolving to Dementia Parallels Parieto-Occipital and Temporal Enlargement in Idiopathic Chronic Hydrocephalus: A Retrospective Cohort Study. Frontiers in Neurology. 2015; 6: 15. https://www.ncbi.nlm.nih.gov/pubmed/25759681. https://www.ncbi.nlm.nih.gov/pmc/articles/4338750. https://doi.org/10.3389/fneur.2015.00015
  11. Naud A, Schmitt E, Wirth M, Hascoet J-M. Determinants of Indices of Cerebral Volume in Former Very Premature Infants at Term Equivalent Age. Simeoni U, ed. PLoS ONE. 2017; 12(1): e0170797. https://doi.org/10.1371/journal.pone.0170797
  12. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology. 2011; 69(2): 292–302. https://www.ncbi.nlm.nih.gov/pubmed/21387374. https://www.ncbi.nlm.nih.gov/pmc/articles/3084507. https://doi.org/10.1002/ana.22366
  13. Tintore M, Rovira A, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis, Brain. 2015 July; 138(7): 1863–74. https://www.ncbi.nlm.nih.gov/pubmed/25902415. https://doi.org/10.1093/brain/awv105
  14. Tompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2017 Feb; 17(2): 162-73. https://www.ncbi.nlm.nih.gov/pubmed/29275977. https://doi.org/10.1016/S1474-4422(17)30470-2